Discussion in 'General ME/CFS Discussion' started by knackers323, Jan 30, 2017.
When are the next results or answers regarding these or other studys like Dr Linkins due? Thanks
Replication efforts of Naviaux's study are taking place, he talks about this in his reply to a comment on his paper.
Lipkin's study has all the samples it needs but needs funding to start, http://bit.ly/DonateToDrLipkin
We will hear about results from the OMF as and when Ron is confident in them I guess, he has no plans to publish results himself.
Fluge and Mella's Stage 3 Rituximab study results will be unblinded in the autumn sometime of this year. They may release the information there and then, or they may wait until they are published officially in which case we won't hear for, probably, 6 months or so.
There are other studies taking place but off the top of my head I'm not aware of when we might see any results from them.
Please note, this is all my interpretation of what I've recently read, so if anybody has any firm info I'm more than happy to be corrected.
From OMF Newsletter 15 December 2016
@AndyPR and @mango are spot on from the OMF side of things, I will also add that OMF and Prof Davis is planning a webinar in February to give some updates
And we have CycloME due around July sometime.
Honestly never heard about that, can someone tell me what it is?
Fluge and Mella testing another cancer drug, in short.
https://helse-bergen.no/seksjon-eng...atment and medical physics/sider/cyclome.aspx
A year ago last December, Dr. Lipkin visited Simmaron Reseach in Incline Village, Nevada. Cort Johnson reported on it here...
...and there was a thread on it here:
One of the developments that Lipkin's team was working on was...
Although the quote referred to the information being embargoed "pending publication" of the paper, it also used the term "preliminary results," so it's hard to tell how far along that study was / is. Hopefully, we'll see more information on this research in the coming year.
You can also try a Google Site Search
Separate names with a comma.